Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610041, China.
Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Cancer Cell. 2023 Feb 13;41(2):272-287.e9. doi: 10.1016/j.ccell.2023.01.001. Epub 2023 Jan 26.
Circulating tumor cells (CTCs), shed by primary malignancies, function as "seeds" for distant metastasis. However, it is still largely unknown how CTCs escape immune surveillance. Here, we characterize the transcriptomes of human pancreatic ductal adenocarcinoma CTCs, primary, and metastatic lesions at single-cell scale. Cell-interaction analysis and functional studies in vitro and in vivo reveal that CTCs and natural killer (NK) cells interact via the immune checkpoint molecule pair HLA-E:CD94-NKG2A. Disruption of this interaction by blockade of NKG2A or knockdown of HLA-E expression enhances NK-mediated tumor cell killing in vitro and prevents tumor metastasis in vivo. Mechanistic studies indicate that platelet-derived RGS18 promotes the expression of HLA-E through AKT-GSK3β-CREB signaling, and overexpression of RGS18 facilitates pancreatic tumor hepatic metastasis. In conclusion, platelet-derived RGS18 protects CTCs from NK-mediated immune surveillance by engaging the immune checkpoint HLA-E:CD94-NKG2A. Interruption of the suppressive signaling prevents tumor metastasis in vivo by immune elimination of CTCs.
循环肿瘤细胞 (CTCs) 由原发性恶性肿瘤脱落,作为远处转移的“种子”。然而,CTC 如何逃避免疫监视在很大程度上仍不清楚。在这里,我们以单细胞水平的方式描绘了人类胰腺导管腺癌 CTCs、原发性和转移性病变的转录组。细胞相互作用分析和体外及体内的功能研究表明,CTC 和自然杀伤 (NK) 细胞通过免疫检查点分子对 HLA-E:CD94-NKG2A 相互作用。通过阻断 NKG2A 或敲低 HLA-E 表达破坏这种相互作用,可增强 NK 介导的肿瘤细胞杀伤作用,并防止体内肿瘤转移。机制研究表明,血小板衍生的 RGS18 通过 AKT-GSK3β-CREB 信号促进 HLA-E 的表达,过表达 RGS18 可促进胰腺肿瘤肝转移。总之,血小板衍生的 RGS18 通过与免疫检查点 HLA-E:CD94-NKG2A 结合,保护 CTC 免受 NK 介导的免疫监视。抑制信号的中断通过免疫消除 CTC 来防止体内肿瘤转移。
J Clin Invest. 2019-3-12
Nature. 1998-2-19
J Neuropathol Exp Neurol. 2005-6
Nat Rev Immunol. 2025-9-3
J Hematol Oncol. 2025-8-22
Cancer Gene Ther. 2025-8-2
Signal Transduct Target Ther. 2025-7-31
Cancer Cell Int. 2025-7-11